DAFTAR PUSTAKA

1. Nurdjanah S. Sirosis hati. Dalam: (Editor: Sudoyo AW, Setiyohadi B, Alwi I, Simadibrata M, Setiati S) Buku Ajar Ilmu Penyakit Dalam jilid I, edisi ke-6. Pusat Penerbitan Departemen Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia. Jakarta: 2014; p.668–73.
2. Kusumobroto HO. Sirosis hati. Dalam: (Editor: Lesmana LA) Buku Ajar Ilmu Penyakit Hati edisi 1 revisi. CV Sagung Seto. Jakarta. 2012; p.347–57.
3. Alvares SMR, Reverbel ST. Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients. Nutrition 2005; 21: 113–7.
4. Jungermann K, Kietzmann T. Oxygen: modulator of metabolic zonation and disease of the liver. Hepatology (Baltimore, Md.). 2000; 31: 255–60.
5. Kietzmann T, Cornesse Y, Brechtel K, Modaressi S, Jungermann K. Perivenous expression of the mRNA of the three hypoxia-inducible factor alpha-subunits, HIF1alpha, HIF2alpha and HIF3alpha, in rat liver. Biochem J. 2001; 354: 531–37.
6. Nath B, Szabo G. Hypoxia and hypoxia inducible factors: diverse roles in liver diseases. NIH Hepatol. 2012 February; 55(2): 622–33.
7. Novo E, Povero D, Busletta C. The biphasic nature of hypoxia induced directional migration of activated human hepatic stellate cells. J Pathol. 2012; 226: 588–97.
8. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001; 292: 468–72.
9. Kim W, Safran M, Buckley M, Ebert B, Glickman J, Bosenberg M, et al. Failure to prolyl hydroxylate hypoxia-inducible factor alpha phenocopies VHL inactivation in vivo. The EMBO journal. 2006; 25: 4650.
10. Dimova EY, Kietzmann T. Hypoxia-inducible factors: post-translational crosstalk of signaling pathways. Methods Mol Biol. 2010. 647: 215–36.

11. Benita Y, Kikuchi H, Smith AD, Zhang MQ, Chung DC, Xavier RJ. An integrative genomics approach identifies Hypoxia Inducible Factor-1 (HIF-1)-target genes that form the core response to hypoxia. Nucleic Acids Res. 2009; 37: 4587–602.
12. Dioum EM, Chen R, Alexander MS, Zhang Q, Hogg RT, Gerard RD, et al. Regulation of hypoxia-inducible factor 2 alpha signaling by the stress-responsive deacetylase sirtuin 1. Sci. 2009; 324: 1289–93.
13. Lehwald N, Tao GZ, Jang KY, Sorkin M, Knoefel WT, Sylvester KG. Wnt-beta-catenin signaling protects against hepatic ischemia and reperfusion injury in mice. Gastroenterol. 2011; 141: 707–718. 718, e701 705.
14. Balogh E, Toth A, Mehes G, Trencsenyi G, Paragh G, Jeney V. Hypoxia triggers differentiation of vascular smooth muscle cells in an HIF-1 (hypoxia-inducible factor 1)-dependent and reactive oxygen species-dependent manner. Am Ass J. 2019; 39: 1088–99.
15. Rankin EB, Rha J, Selak MA, Unger TL, Keith B, Liu Q, et al. Hypoxia inducible factor regulates hepatic lipid metabolism. ASM. Mol Cell Biol. 2009: p.4527–38.
16. Pratt DS, Kaplan MM. Evaluation in liver function. In: (Editor: Fauci AS, Kasper D, Jameson L, Hauser SL, Loscalzo J) Harrison's Principles of Internal Medicine. 19th ed. Mc Graw Hill, New York. 2017: p.1813–5.
17. Henry JB. Evaluation of liver function and injury. In: (Editor: W.B. Saunders) Clinical Diagnosis and Management by Laboratory Methods 20th edition. Philadelphia. 2001; p. 267–9.
18. Setiawati M. Perbandingan validitas maddrey's discriminant fuction dan skor child-turcotte-pugh dalam memprediksi ketahanan hidup 12 minggu pada pasien sirosis hati. Semarang. Fakultas Kedokteran Universitas Diponegoro. 2009. Tesis.
19. Doubatty AC. Perbandingan validitas skor mayo end stage liver disease dan skor child-turcotte-pugh dalam memprediksi ketahanan hidup 12 minggu pada pasien sirosis hati. Semarang. Fakultas Kedokteran Universitas Diponegoro. 2009. Tesis.

20. Sitorus J. Korelasi skor child-turcotte-pugh dengan kadar glukosa darah pada penderita sirosis hati. Medan. Fakultas Kedokteran Universitas Sumatera Utara / Rumah Sakit H. Adam Malik. 2008. Tesis.
21. Wilson G, Tennant D, McKeating J. Hypoxia inducible factor in liver disease and hepatocellular carcinoma: current understanding and future directions. European Association For The Study Of The Liver. J Hepatol. 2014 vol.61: 1397–1406.
22. Hutchinson GJ, Valentine HR, Loncaster JA, Davidson SE, Hunter RD, Roberts SA, et al. Hypoxia inducible factor-1α expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clinical cancer research. Am Assoc for Cancer. 2004. Vol.10, 8405–12.
23. Liang X, Yang D, Hu J, Hao X, Gao J, Mao Z. Hypoxia inducible factor-1α expression correlates with vascular endothelial growth factor-c expression and lymphangiogenesis / angiogenesis in oral squamous cell carcinoma. Anticancer Res. 2008; 28: 1659–66.
24. Das RN, Mukherjee S, Sharma I. Alkaline phosphatase determinants of liver patients. J Panc. 2018; 19: 18–23.
25. Kratz A. The plasma proteins. In: (Editor: Lewandrofwski, Kent) Clinical Chemistry: Laboratory Management and Clinical Correlations. Lippincott Wiliam & Wilkins. Philadelphia, USA. 2002: p.32-7.
26. Acharya G, Kaushik RM, Gupta R, Kaushik R. Child-turcotte-pugh score, meld score, and meld-na score as predictors of short-term mortality among patients with end-stage liver disease in northern india. Inflam Intestin Dis. 2019; 5: 1-10.
27. Ju C, Colgan SP, Eltzschig HK. Hypoxia inducible factors as molecular targets for liver diseases. JMolMed. Springer. 2016; 94: 613–27.
28. Cheney CP, Goldberg EM, Chopra S. Cirrhosis and portal hypertension; an overview. In: (Editor: Friedman LS, Keeffe EB) Handbook of Liver Disease. 2nd ed. China, Pa: Churchill Livingstone; 2004: p.125–38.

29. Friedman SL. Hepatic fibrosis. In: (Editor: Schiff ER, Sorrell ME, Maddrey WC) Schiff's Disease of the Liver. 9th ed. Philadelphia, Pa: Lippincott-Raven; 2003: 409–28.
30. Ohh M, Park CW, Ivan M. Ubiquitination of hypoxia inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000; 2: 423–27.
31. Lando D, Peet DJ, Gorman JJ. FIH-1 is an asparaginyl hydroxylase enzyme that regulates the transcriptional activity of hypoxia-inducible factor. Genes Dev. 2002; 16: 1466–71.
32. Hu JL, Liu LP, Yang SL. Hepatitis B virus induces hypoxia inducible factor-2 alpha expression through hepatitis B virus X protein. Oncol Rep. 2015; 1.
33. Liu LP, Hu BG, Ye C. HBx mutants differentially affect the activation of hypoxia-inducible factor-1 alpha in hepatocellular carcinoma. Br J Cancer. 2014; 110:1066–73.
34. Campbell EL, Bruyninckx WJ, Kelly CJ. Transmigrating neutrophils shape the mucosal microenvironment through localized oxygen depletion to influence resolution of inflammation. Immunity. 2014; 40: 66–77.
35. Cramer T, Yamanishi Y, Clausen BE. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell. 2003; 112: 645–57.
36. Aherne CM, Saeedi B, Collins CB. Epithelial-specific A2B adenosine receptor signaling protects the colonic epithelial barrier during acute colitis. Mucosal Immunol. 2015; 8: 699.
37. Colgan SP, Eltzschig HK. Adenosine and hypoxia inducible factor signaling in intestinal injury and recovery. Annu Rev Physiol. 2012; 74:153–175.
38. Eshaghian A, Khodarahmi A, Safari F, Binesh F, Moradi A. Curcumin attenuates hepatic fibrosis and insulin resistance induced by bile duct ligation in rats. BJN. 2018; 120:393–403.
39. Nath B, Szabo G. Alcohol induced modulation of signaling pathways in liver parenchymal and non parenchymal cells; implications for immunity. Semin Liver Dis. 2009; 29: 166–77.

40. Abe Y, Uchinami H, Kudoh K. Liver epithelial cells proliferate under hypoxia and protect the liver from ischemic injury via expression of HIF-1 alpha target genes. Surgery. 2012; 152: 869–78.
41. Yamada S, Utsunomiya T, Morine Y. Expressions of hypoxia inducible factor 1 and epithelial cell adhesion molecule are linked with aggressive local recurrence of hepatocellular carcinoma after radiofrequency ablation therapy. Ann Surg Oncol 21 (Suppl 3). 2014; S436–42.
42. Lee YM, Lim JH, Yoon H, Chun YS, Park JW. Antihepatoma activity of chaetocin due to deregulated splicing of hypoxia inducible factor-1α pre-mRNA in mice and in vitro. Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine. AASLD. 2011; 171–80.
43. Scharte M, Han X, Uchiyama T, Tawadrous Z, Delude R, Fink M. LPS increases hepatic HIF-1alpha protein and expression of the HIF-1 dependent gene aldolase A in rats. J Surg. 2006; 135: 262–67.
44. Van Uden P, Kenneth N, Rocha S. Regulation of hypoxia-inducible factor 1 alpha by NF-kappa B. Biochem J. 2008; 412:477–84.
45. Moon J, Welch T, Gonzalez F, Copple B. Reduced liver fibrosis in hypoxia inducible factor 1 alpha deficient mice. American journal of physiology. Gastroint and liver physiol. 2009; 296: G 582–92.
46. Corpechot C, Barbu V, Wendum D, Kinnman N, Rey C, Poupon R, et al. Hypoxia induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology. 2002; 35: 1010–21.
47. Novo E, Cannito S, Zamara E, Valfre di Bonzo L, Caligiuri A, Cravanzola C, et al. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. Am J of Pathol. 2007; 170: 1942–53.
48. Shi YF, Fong CC, Zhang Q, Cheung PY, Tzang CH, Wu RS. Hypoxia induces the activation of human hepatic stellate cells LX-2 through TGF-beta signaling pathway. FEBS Lett. 2007; 581: 203–10.

49. Shipman KE, Holt AD, Gama R. Interpreting an isolated raised serum alkaline phosphatase level in an asymptomatic patient. BMJ. 2013; 346: f976.
50. Hess B. Biochemistry and biology of plasma enzymes. In: Enzymes in blood plasma. Academic Press. 2007: 5–68.
51. Li G, Lu WH, Ai R, Yang JH, Chen F, Tang ZZ. The relationship between serum hypoxia inducible factor 1 α and coronary artery calcification in asymptomatic type 2 diabetic patients. Card Diabet J. 2014; 13: 52.
52. Li S, Yao D, Wang L, Wu W, Qiu L, Yao M, et al. Expression characteristics of hypoxia-inducible factor-1α and its clinical values in diagnosis and prognosis of hepatocellular carcinoma. Hepatitis Monthly. 2011; 11(10): 821–28.
53. Rong B, Liu Y, Li M, Fu T, Gao W, Liu H. Correlation of serum levels of HIF-1α and IL-19 with the disease progression of COPD: a retrospective study. Int J of COPD 2018: 13; 3791–803.
54. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLB. Update 2017.
55. Mohsin S, Farhan S, Nadeem MA, Rasheed S, Yousaf S. Frequency of minimal hepatic encephalopathy in cirrhotic patients with normal neurological examination. Department of Medicine unit III. Hepatol Int of Med Sci. Lahore. 2016; PJMHS Vol 10 No.2.
56. Hameed L, Ogbera AO, Onyekwere CA. Chronic liver disease and hepatic encephalopathy: critical profile and outcomes. Niger J Clin Pract. 2011; 14(2): 181–5.
57. Santoso M, Tendean M, Wician F, Sujana DS, Ndraha S. Tes critical flicker frequency pada sirosis hati di RSUD Koja. JKM. 2010; 16 (42): 1–10.
58. Wunsch E, Post M, Gutkowski, Marlicz W, Szymanik B, Hartleb M, et al. Digestive and liver disease. 2010; 42: 818–21.

59. Bugarsky V, Klasnja B, Filipovic D, Brkic S, Ruzic M, Maric D. Minimal hepatic encephalopathy in patients with decompensated liver cirrhosis. Acta Clin Croat. 2011; 50(3): 375–80.
60. Sarin SK, Sharma BC, Puri V, Sharma P. Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. J of hepatol. 2007; 4: 67–73.
61. Hasan I, Sanitiyoso A, Setiati S. The effects of branched chain amino acids and l-ornithine l-aspartate combination as the late evening snack on nutritional status and minimal hepatic encephalopathy in liver cirrhosis. Ind J Hepatol. 2013. Volume 3. P. 1-3
62. Kucera J, Netusilova J, Sladecek S, Lanova M, Vasicek O, Stefkova K, et al. Hypoxia downregulates MAPK/ERK but not STAT3 signaling in ROS-dependent and HIF-1 independent manners in mouse embryonic stem cells. International Clinical Research Centre, Czech Republic. Hindawi: Ox Med and Cell. 2017. P. 1–16.